Doctiplus - We are allways here!
Cancer & Oncology
Weekly Report
- 182 new clinical trials registered across 10 countries.
- 18,870 trials actively recruiting patients worldwide.
- Notable trial: A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HE... (3800 patients).
- 2,940 new research papers published.
- Top cited: "Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck ..." (JCO global oncology, 1 citations).
- Drug safety: Most reported effect across tracked medications (pembrolizumab, nivolumab, trastuzumab, rituximab, paclitaxel) was Off Label Use.
- No active drug recalls for tracked medications this week.
The week in numbers
Trials by country
Trials by phase
New clinical trials registered this week for Cancer & Oncology. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.
This week's new registrations
182 trials registered for Cancer & Oncology. Each links to its full record on ClinicalTrials.gov.
Adverse event reports
Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Cancer & Oncology. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.
Reports by drug
| Drug | Top effect | Count |
|---|---|---|
| pembrolizumab | Malignant Neoplasm Progression | 1,762 |
| nivolumab | Off Label Use | 819 |
| trastuzumab | Myelosuppression | 707 |
| rituximab | Off Label Use | 5,213 |
| paclitaxel | Myelosuppression | 1,062 |
Recalls & safety notices
FDA drug recall notices for medications related to Cancer & Oncology. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.
No active drug recalls for tracked medications this period.
Published research
Recently published peer-reviewed studies related to Cancer & Oncology, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.
| # | Study | Journal | Date | Source |
|---|---|---|---|---|
| 01 |
USP4-Mediated Deubiquitination of PTBP1 Promotes Glioma Progression and Radioresistance by Enhancing PHB2-Dependent Mitophagy.
View abstractMitophagy plays a key role in glioma radioresistance, but its upstream regulatory mechanism is not fully understood. This study aims to investigate the function and potential molecular mechanism of polypyrimidine tract-binding protein 1 (PTBP1) in mitophagy and radioresistance of glioma. The GSE16011 dataset was used to screen the differentially expressed genes, combined with weighted gene co-expression network analysis and machine learning to screen the key genes related to mitophagy in glioma. The expression levels of PTBP1, ubiquitin-specific protease 4 (USP4) and prohibitin 2 (PHB2) were detected by qRT-PCR and western blot. After transfection of overexpression vectors and shRNAs, EdU, flow cytometry, JC-1 staining, MitoSOX staining, and clonogenic survival assays were used to evaluate cell proliferation, apoptosis, mitochondrial membrane potential, ROS level, and radiosensitivity under 8 Gy irradiation. The interaction between PTBP1 and PHB2 mRNA was verified by RIP, dual-luciferase reporter assay and actinomycin D assay. Co-IP, ubiquitination assay and cycloheximide experiment were used to verify the deubiquitination regulation of USP4 on PTBP1. The effect of USP4/PTBP1 axis on the radioresistance of glioma in vivo was verified by constructing a subcutaneous xenograft tumor model combined with 10 Gy irradiation. Bioinformatics analysis identified PTBP1 as a key gene related to mitophagy in glioma, which was highly expressed in glioma tissues and cells. PTBP1 overexpression promoted glioma cell proliferation, inhibited apoptosis, enhanced mitophagy, maintained mitochondrial membrane potential, reduced mitochondrial ROS level, and promoted radioresistance under the irradiation conditions. These effects were reversed by mitophagy inhibitor BafA1. Mechanistically, PTBP1 directly bound to the 3'UTR of PHB2 to enhance its mRNA stability and expression. Overexpression of PHB2 reversed the inhibitory effect of PTBP1 knockdown on mitophagy and radioresistance. Moreover, USP4 inhibited the degradation of PTBP1 by deubiquitination to stabilize its protein level. USP4 knockdown inhibited mitophagy and radioresistance, while PTBP1 overexpression reversed these effects. In vivo experiments further confirmed that USP4 overexpression promoted glioma radioresistance and tumor growth, while PTBP1 knockdown abolished these effects. USP4 stabilizes PTBP1 protein to enhance PHB2 mRNA stability, thereby promoting mitophagy and driving glioma radioresistance. Targeting the USP4/PTBP1/PHB2 axis may represent a potential strategy to sensitize glioma cells to radiation, although this requires further validation with appropriate 0 Gy controls and direct mitophagic flux assays. |
Molecular carcinogenesis | 2026 Oct 25 | PubMed |
| 02 |
Programmed Drug Release from Triple Stimuli-Responsive Poly(N-vinylcaprolactam)-b-Poly(ε-caprolactone) Copolymer Nanoassemblies with Enhanced Encapsulation through Noncovalent Interactions in the Core.
View abstractMulti-stimuli-responsive biodegradable polymeric nanoassemblies with high encapsulation ability, micellar stability, and programmed intracellular drug release are highly attractive for efficient cancer therapy. Herein, an amphiphilic diblock copolymer responsive to three endogenous stimuli of a cancer cell is synthesized using temperature-responsive poly(N-vinylcaprolactam) as a macroinitiator for the ring-opening polymerization of chloroalkyl-substituted ε-caprolactone. Phenyl and triazole rings are incorporated in the side chain to link a redox-responsive disulfide group to a hydrophobic block using click chemistry. The diblock copolymer self-assembles in aqueous medium into spherical micelles with an average hydrodynamic diameter of 140-150 nm. High dye encapsulation efficiency and stability are verified by fluorescence resonance energy transfer and isothermal titration calorimetry studies. Copolymer nanoassemblies display ill-defined aggregates at tumor-relevant temperatures (40-43 °C), glutathione-induced swelling, and esterase-mediated complete micellar disassembly. Combined effect of triple stimuli on drug release is observed compared to the release in response to individual stimuli. The diblock copolymer shows excellent biocompatibility with MCF-7 and MDA-MB-231 cancer cells, and DOX-loaded copolymer nanoassemblies show cytotoxicity toward the cancer cells, augmented by low IC50 values (6.37 and 4.58 μg/mL). Cellular uptake and time-dependent drug release in cancer cells are demonstrated. |
ACS applied bio materials | 2026 Oct 25 | PubMed |
| 03 |
Molecular mechanisms and targeted therapeutic strategies of TIGAR in regulating energy metabolism to promote tumor proliferation in breast cancer.
View abstractBreast cancer is the most common malignancy among women worldwide and is closely associated with metabolic reprogramming during malignant progression. TIGAR (TP53-Induced Glycolysis and Apoptosis Regulator) is highly expressed in a substantial proportion of human breast cancers and has emerged as an important regulator of tumor metabolism. However, the molecular network through which TIGAR promotes breast cancer progression and its clinical translational potential remain incompletely understood. This review summarizes the molecular mechanisms underlying the oncogenic functions of TIGAR in breast cancer, including regulation of cell-cycle progression through the p21-CDK2 axis, activation of the c-Myc/HIF-1α positive-feedback loop and the STAT3-mediated immune-metabolic axis, suppression of ROS-dependent apoptosis and ferroptosis, and remodeling of oxidative phosphorylation and lipid metabolism. Clinically, high TIGAR mRNA expression has been associated with shorter progression-free survival in breast cancer (HR = 1.56, P = 1.9 × 10⁻⁸), and this association remained significant after multivariable adjustment in an analysis of publicly available breast cancer transcriptomic and clinical outcome datasets. However, the prognostic significance of TIGAR requires further validation in independent clinical cohorts. Preclinical studies further suggest that metabolic interventions targeting mitochondrial function, nanomedicine-based strategies, and modulation of cholesterol metabolism may counteract TIGAR-associated tumor-promoting effects. This review integrates current evidence on the molecular and metabolic functions of TIGAR in breast cancer and discusses the opportunities and challenges of targeting TIGAR as part of combination metabolic therapies. |
Breast cancer (Tokyo, Japan) | 2026 Oct 25 | PubMed |
| 04 |
Peripheral immune tolerance as a driver of tumor immune escape and therapy resistance.
View abstractPeripheral immune tolerance, essential for preventing autoimmunity, is increasingly co-opted by tumors to drive progression, metastatic dissemination, and immunotherapy resistance. Whereas central tolerance eliminates autoreactive clones, peripheral tolerance remains dynamically regulated by antigen persistence, cytokine gradients, metabolic cues, and stromal architecture, a plasticity that tumors exploit to build a multilayered immunosuppressive ecosystem. This narrative review synthesizes multi-omic, spatial, cellular, and molecular evidence, emphasizing 2021 to 2025 publications alongside foundational studies, to propose tumor-induced peripheral tolerance (TIPT) as a unifying framework for immune escape and treatment failure. TIPT emerges from coordinated suppression by tumor-resident regulatory T cells, myeloid-derived suppressor cells, regulatory B cells, M2-like macrophages, tolerogenic dendritic cells, and exhausted CD8? T cells, sustained by suppressive cytokine networks, metabolic deprivation, epigenetic fixation of dysfunctional states, and stromal-vascular exclusion barriers. Spatially organized tolerance niches are associated with immune evasion, metastatic seeding, and resistance to checkpoint blockade. Strategies targeting suppressive cell populations, metabolic pathways, chromatin regulators, and stromal barriers are in clinical development, but clinical benefit has been established for only a limited subset, and anti-TIGIT antibodies failed to meet primary endpoints in phase 3 lung cancer trials. Machine-learning models show promise for predicting tolerance states and guiding combination design, but prospective clinical validation is still needed. TIPT may represent an important, potentially actionable determinant of tumor evolution and immunotherapy response, and durable cancer control is likely to require combined strategies that dismantle this tolerance ecosystem. |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2026 Oct 25 | PubMed |
| 05 |
The role of hope and its association with quality of life in individuals with chronic pain - insights from a daily diary study.
View abstractPURPOSE: Hope has been identified as a beneficial factor for enhancing quality of life (QoL), particularly for individuals with chronic disease, including chronic pain. However, significant gaps remain in understanding how hope and QoL intersect and relate to one another. The current study investigated whether daily hope frequency, defined as how often participants felt hopeful each day, can predict next-day QoL among individuals with chronic pain who are using cannabis and opioids to manage pain. METHODS: This was an observational study, approved by the Institutional Review Board of the Johns Hopkins Bloomberg School of Public Health (Protocol: IRB00009327). Participants (N = 132) using opioids and cannabis for chronic pain completed a baseline survey and 30-day daily diaries assessing hope frequency, QoL, and sleep satisfaction. Participants (mean age = 42.7, SD = 13.9) were predominantly male (58.3%) and Non-Hispanic White (63.6%). Linear mixed-effects models were used to test the lagged effects of daily hope frequency, decomposed into between- and within-person components, on next-day QoL, controlling for baseline variables, daily sleep satisfaction, and previous-day QoL. Intraindividual variabilities were also examined. RESULTS: Higher hope frequency was significantly associated with greater next-day QoL both between participants (i.e., participants with higher average hope reported higher QoL) and within participants (i.e., on days when hope was higher than a participant's own average), even after controlling for previous-day QoL and sleep satisfaction. While higher baseline hope and QoL scores were associated with higher average QoL over the 30-day period, intraindividual variability in hope was not significantly associated with QoL. CONCLUSIONS: Our daily diary study found that previous-day hope frequency - both stable individual differences and day-to-day fluctuations - was associated with next-day QoL in individuals with chronic pain who were co-using cannabis and opioids. |
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation | 2026 Oct 25 | PubMed |
| 06 |
Proteomic profiling of somatotropinoma subtypes reveals TNIP1 overexpression in sparsely granulated tumors in a small discovery cohort.
View abstractBACKGROUND: The molecular mechanisms underlying the clinical differences between densely granulated (DG) and sparsely granulated (SG) somatotroph tumors remain poorly understood. To identify significant molecular differences between these subtypes, we performed quantitative mass spectrometry-based proteomic profiling followed by validation of the differentially-identified proteins. METHODS: Label-free quantitative proteomic analysis was performed on SG somatotroph adenomas (SGSAs, n = 3) and DG somatotroph adenomas (DGSAs, n = 3), with each sample analyzed in technical triplicate. Key findings were subsequently validated using immunohistochemistry (IHC, n = 64), immunofluorescence (IF, n = 24), and Western blotting (WB, n = 18). RESULTS: Proteomic profiling identified TNFAIP3-interacting protein 1 (TNIP1) as the most significantly over-expressed protein, and coenzyme Q6 monooxygenase (COQ6) as the most significantly under-expressed protein, in SGSAs compared with DGSAs. Higher TNIP1 expression in SGSAs was significantly associated with IGF-1 [%ULN], larger tumor diameter, greater tumor volume, higher Knosp grade and SSTR5 expression. In contrast, COQ6 expression showed significant negative correlations with tumor diameter, tumor volume, Knosp grade, and SSTR5 expression. These findings indicate strong associations between TNIP1 and COQ6 expression and tumor characteristics, along with differences in cell adhesion and signaling pathways. CONCLUSIONS: SGSAs and DGSAs exhibit distinct proteomic profiles. Increased TNIP1 and reduced COQ6 expression, together with alterations in cell adhesion and signaling pathways in SGSA, may contribute to the molecular and phenotypic differences underlying these somatotroph tumor subtypes. |
Pituitary | 2026 Oct 25 | PubMed |
| 07 |
Prognostic associations between patient-reported outcomes and progression-free and overall survival in advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 TAP score ≥ 5%: results from the RATIONALE-305 trial.
View abstractPURPOSE: In RATIONALE-305, tislelizumab plus chemotherapy improved overall survival (OS) versus placebo plus chemotherapy in advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) with programmed death-ligand 1 (PD-L1) tumor area positivity (TAP) score ≥ 5% and in all patients. Here, we present a three-component joint model (JM) developed to evaluate associations between patient-reported outcomes (PROs) and risk of progression-free survival (PFS) and OS events. METHODS: Longitudinal PRO data were analyzed using the EORTC QLQ-C30 and QLQ-STO22. The JM linked: (1) a linear mixed model (LMM) for change from baseline in PRO scores; (2) a Cox model for time to recurrent symptomatic deterioration (RS-D); and (3) a Cox model to evaluate the RS-D event frailty prediction of PFS and OS. RESULTS: 475 patients in the PD-L1 ≥ 5% subgroup (tislelizumab + chemotherapy, n = 238; placebo + chemotherapy, n = 237) were evaluated. In PFS and OS LMMs, tislelizumab + chemotherapy versus placebo + chemotherapy was associated with improved GHS/QoL (global health status/quality of life) (p = 0.01) and reduced dietary restrictions (p = 0.05). In the OS LMM, tislelizumab + chemotherapy was associated with reduced upper GI symptoms (p = 0.01) and reductions in dietary restrictions (p = 0.02). RS-D in GHS/QoL, pain, and dietary restrictions were leading predictors of PFS risk. Across all QLQ-C30 and QLQ-STO22 domains, tislelizumab plus chemotherapy significantly reduced the risk of progression or death (PFS HRs 0.55-0.65; 35-45% reduction) and death (OS HRs 0.65-0.73; 27-35% reduction); all p ≤ 0.01. CONCLUSION: PROs have significant prognostic value for disease progression and survival in patients with PD-L1 TAP score ≥ 5%. REGISTRATION NUMBER: NCT03777657 ( http://clinicaltrials.gov ). |
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation | 2026 Oct 25 | PubMed |
| 08 |
Androgen receptor signaling in hepatocellular carcinoma: mechanisms of male predominance and therapeutic opportunities.
View abstractHepatocellular carcinoma (HCC) is two to four times more common in men than in women. The sex distribution of viral hepatitis, alcohol use and adiposity explains only part of this difference, which points to sex-specific host biology as a further driver. The androgen receptor (AR), a ligand-activated transcription factor expressed in hepatocytes and in most HCC, is a strong candidate: both epidemiologic and experimental data implicate it in the male excess. This review draws that evidence together. Prospective cohorts link higher circulating testosterone and sex hormone-binding globulin to liver cancer risk, although raising SHBG experimentally suppresses rather than promotes hepatocarcinogenesis, a discordance that bears on how those associations should be read, and experimental studies group the underlying biology into several modules: constitutively active AR and its splice variants, kinase-driven phosphorylation of the receptor, downstream effectors of proliferation, invasion and angiogenesis, non-coding RNA circuits, androgen-metabolizing enzymes and the systemic endocrine axis, and the effect of androgen on the tumor immune microenvironment. The weight of each module differs across hepatitis B virus (HBV)-related, hepatitis C virus (HCV)-related, metabolic dysfunction-associated and anabolic steroid-induced disease. Therapeutic work remains largely preclinical and has centered on AR antagonists combined with tyrosine kinase inhibitors or immune checkpoint blockade, on degraders aimed at AR splice variants, on proteolysis-targeting chimeras and nucleic-acid approaches that eliminate ligand-independent receptor states, and on enzyme inhibitors. Two problems still limit translation: AR appears oncogenic in most settings but tumor-suppressive in some, and androgen suppresses antitumor immunity in certain contexts while enhancing it in others. Clarifying when each holds is what will determine whether AR-directed therapy, already established in prostate cancer, can be extended to liver cancer. |
Molecular biology reports | 2026 Oct 25 | PubMed |
| 09 |
Analysis the ovotoxicity and ovarian cancer stem-like progenitors generation in benzo[a]pyrene-treated Mice.
View abstractBACKGROUND: Benzo(a)pyrene (BaP), a member of the polycyclic aromatic hydrocarbon (PAH) family, is a potent carcinogen and causes cancer in multiple organs. The present research investigates the toxicity of BaP in the reproductive tract of female Swiss mice. METHODS AND RESULTS: A standardised dose of BaP (50 mg/kg body weight twice a week for one month) was administered to induce systemic oxidative stress in murine models. After 4 months, BaP administration reduces the numbers of primordial and primary ovarian follicles and induces stromal cell hyperplasia and inflammation inside the ovary. The thickness of uterine layers decreases, while the diameter of the uterine lumen and number of uterine glands rise. Atrophied uterine linings, as well as endometrial hyperplasia (EH) with abnormal glandular development are apparent. Using flow cytometry, three different ovarian cancer stem-like progenitors (CSLP) were identified based on the expression of CD44 and CD133 receptors: CD44⁺CD133⁻, CD44⁺CD133⁺, and CD44CD133. BaP treatment increases CD44CD133(7.3-fold, p < 0.005) and CD44CD133 cells (2.53-fold, p < 0.0005), while decreasing CD44CD133 cells (52% reduction, p < 0.0005). BaP administration also increases the CD44 (4-fold, P < 0.0005) and CD133 surface expression (47% increase, p < 0.005) as well as ROS production (2-fold increment, p < 0.005) in ovarian cells. The RT-qPCR data suggests a marked reduction in the relative expressions of antioxidant genes (SOD1, SOD2, catalase, GPX1, and FOXO3) in ovarian cells. CONCLUSIONS: BaPadministration disrupts folliculogenesis, reduces ovarian follicle size, and causes epithelial hyperplasia, lymphocytic infiltration, increased vascularisation, atrophied uterine lining, and abnormal glandular growth in the uterus. It induces CSLPs and CD44 and CD133 expression in ovaries. The BaP administration also increases ROS and decreases antioxidant gene expression in the ovaries. |
Molecular biology reports | 2026 Oct 25 | PubMed |
| 10 |
Evaluation of FGFR2, VEGFA, and MMP1 gene variants for ovarian cancer susceptibility among South Indian women: a hospital-based case-control study.
View abstractBACKGROUND: Ovarian cancer (OC) is a genetically heterogeneous malignancy characterized by marked molecular and histologic heterogeneity. Genetic variation in pathways involved in angiogenesis and extracellular matrix remodeling may contribute to OC susceptibility. The present study evaluated VEGFA rs833061, FGFR2 rs1219648, and MMP1 rs1799750 polymorphisms in a South Indian cohort and investigated their individual and combined associations with OC risk. METHODS: This hospital-based pilot case-control study included 240 histopathologically confirmed OC cases and 254 cancer-free controls. Genotyping was performed using PCR-RFLP and allele-specific PCR. Associations with OC susceptibility were assessed using logistic regression with adjustment for age and menopausal status, with the codominant model as the primary genetic model and alternative models as secondary analyses. Exploratory clinicopathological and multifactor dimensionality reduction (MDR) analyses were also performed. RESULTS: MMP1 rs1799750 was associated with increased OC susceptibility, with the 2G/2G genotype showing higher odds of OC (aOR = 2.10, 95% CI = 1.12-3.94; p = 0.0179). Similarly, VEGFA rs833061 was also associated with increased susceptibility, with T/C and C/C genotypes showing higher odds (aOR = 2.51, 95% CI = 1.55-4.06; p = < 0.001 and aOR = 1.87, 95% CI = 1.04-3.35; p = 0.021, respectively). However, FGFR2 rs1219648 was not associated with overall OC susceptibility but showed exploratory associations with selected clinicopathological characteristics. The two-locus VEGFA-MMP1 MDR model showed the highest testing balanced accuracy among evaluated models (TBA = 0.5853; CVC = 10/10). CONCLUSION: VEGFA and MMP1 variants showed associations with OC susceptibility in this South Indian cohort. Combined-genotype and MDR findings are hypothesis-generating and require validation in larger, independent cohorts. |
Molecular biology reports | 2026 Oct 25 | PubMed |
| 11 |
miR-138-5p: From Multidimensional Tumor-Suppressive Regulatory Networks to Nanocarrier-Based Delivery for Solid Tumor Therapy.
View abstractBACKGROUND: MicroRNA-138-5p (miR-138-5p) has been reported to exert tumor-suppressive effects in several solid tumors, and its downregulation has been associated with malignant progression, therapeutic resistance, and poor prognosis. OBJECTIVE: This review summarizes research trends and current evidence on the molecular functions, regulatory networks, and therapeutic potential of miR-138-5p in solid tumors, with particular emphasis on competing endogenous RNA (ceRNA) regulation and nanocarrier-based delivery strategies. METHODS: Bibliometric analysis and CiteSpace visualization were conducted using English-language original articles and reviews retrieved from the Web of Science Core Collection from January 2014 to October 2025. Relevant literature was reviewed to examine miR-138-5p expression, biological functions, target genes, signaling pathways, ceRNA networks, and therapeutic strategies. Studies focused exclusively on hematological malignancies were excluded. RESULTS: Bibliometric mapping identified research clusters spanning multiple solid tumor types, cell-cycle regulation, and proliferation, while metabolic reprogramming and therapeutic resistance emerged as relevant research themes. Mechanistic studies suggest that miR-138-5p regulates proliferation, apoptosis, migration, invasion, autophagy, immune-related signaling, and chemosensitivity through diverse targets and pathways. Long non-coding RNA- and circular RNA-mediated ceRNA networks have been proposed as an additional regulatory layer, although their physiological relevance requires further quantitative validation. Preclinical findings, including exosome-mediated delivery of miR-138-5p, suggest potential for replacement therapy; however, challenges involving delivery efficiency, tumor specificity, biosafety, pharmacokinetics, and manufacturing standardization remain. CONCLUSION: miR-138-5p is a potential biomarker and therapeutic target in solid tumors. Further validation of its context-dependent mechanisms and optimization of targeted delivery strategies are needed to support clinical translation. |
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences | 2026 Oct 25 | PubMed |
| 12 |
The evolving dynamics of OSCC- Associated stromal remodeling from tumor initiation to therapy: The "Dark Side" of tissue repair.
View abstractOral squamous cell carcinoma (OSCC) develops within a highly regenerative mucosa but progressively remodels its surrounding tissue to support invasion, immune evasion, recurrence, and therapeutic adaptation. This review conceptualizes OSCC as a chronic, non-resolving wound-like state in which physiological tissue-repair programs become maladaptively co-opted. Tumor-driven remodeling involves extracellular-matrix (ECM) degradation, laminin reorganization, LOX-mediated matrix stiffening, cancer-associated fibroblast (CAF) heterogeneity, vascular alterations, and immune-stromal interactions at spatially defined niches such as invasive fronts. Surgical resection subsequently imposes acute tissue injury and wound-healing responses that can modify platelet, inflammatory, fibroblast, immune, and ECM programs within the surgical bed and histologically defined margins. Radiotherapy and chemotherapy introduce additional, non-equivalent remodeling trajectories involving oxidative stress, DNA damage, endothelial injury, fibrosis, matrix turnover, hypoxia, and immune modulation. Immune checkpoint inhibition acts upon this pre-existing and treatment-conditioned microenvironment, with heterogeneous CAF, myeloid, endothelial, and lymphoid organization influencing therapeutic response or resistance. Across these contexts, stromal remodeling is therefore dynamic rather than a static feature of the tumor microenvironment, and treatment-associated changes cannot always be distinguished from pre-existing tumor-driven alterations. We propose that this represents the "dark side" of tissue repair, whereby processes essential for tissue restoration may become permissive to tumor persistence and treatment adaptation. Integrating spatially resolved stromal and immune features with established clinicopathological factors may improve recurrence-risk stratification and therapeutic selection. Longitudinal studies are needed to distinguish transient repair responses from persistent tumor-permissive remodeling and to identify actionable stromal states in OSCC. |
Medical oncology (Northwood, London, England) | 2026 Oct 25 | PubMed |
| 13 |
PSMB7 is associated with DNA damage repair and immune microenvironment features and serves as a prognostic biomarker.
View abstractBACKGROUND: The clinical significance and biological roles of PSMB7 in lung adenocarcinoma (LUAD) remain incompletely understood. This study aimed to comprehensively characterize PSMB7 expression, prognostic value, epigenetic regulation, immune associations, and in vitro functions in LUAD. METHODS: PSMB7 expression, clinicopathological associations, prognostic value, epigenetic regulation, co-expression networks, functional pathways, and relationships with the tumor immune microenvironment were systematically evaluated across multiple datasets. External validation was performed in the GSE31210 cohort. Prognostic nomogram performance was additionally evaluated using Harrell's concordance index (C-index) and time-dependent decision curve analysis (DCA). In vitro experiments, including Western blotting, CCK-8 assays, and flow cytometry, were conducted to assess the effects of PSMB7 on cell proliferation and irradiation-induced apoptosis in LUAD cell lines. RESULTS: PSMB7 was significantly upregulated in LUAD and was associated with advanced pathological T and N stages and overall clinical stage. ROC analysis indicated that PSMB7 showed potential discriminatory ability between LUAD and normal lung tissues. High PSMB7 expression independently predicted unfavorable outcomes across multiple prognostic endpoints. Nomogram evaluation using calibration, C-index, and DCA provided complementary evidence for prognostic performance. PSMB7 hypomethylation was associated with poorer survival. PSMB7 expression was positively correlated with DNA mismatch repair genes, RNA modification regulators, and malignant tumor phenotypes. GSEA showed significant enrichment of oncogenic, cell-cycle, metabolic, DNA-repair, and stress-response pathways. In addition, PSMB7 expression was strongly associated with immune scores, immune-cell infiltration, and the expression of immune modulators, MHC molecules, chemokines, and chemokine receptors in LUAD. In vitro, PSMB7 knockdown suppressed cell proliferation and enhanced irradiation-induced apoptosis, whereas PSMB7 overexpression promoted proliferation and reduced apoptosis after irradiation. CONCLUSION: PSMB7 is a candidate independent prognostic biomarker in LUAD and is associated with malignant progression, immune microenvironment features, and cellular responses to irradiation consistent with a potential role in radioresistance. These findings support PSMB7 as a potential therapeutic target in LUAD. |
Molecular biology reports | 2026 Oct 25 | PubMed |
| 14 |
Preparation and characterization of Kaempferol-loaded Niosomes and their effects on apoptosis and cell migration in SKOV3 ovarian cancer cells.
View abstractBACKGROUND: Ovarian cancer remains one of the most lethal gynecological malignancies worldwide, underscoring the urgent need for more effective therapeutic strategies. Kaempferol, a naturally occurring flavonoid with well-documented anticancer properties, has attracted considerable attention because of its antiproliferative and pro-apoptotic activities. However, its therapeutic application is limited by poor aqueous solubility, low bioavailability, and limited cellular availability, which restrict its clinical potential. METHODS: Kaempferol-loaded niosomes (KMF Niosomes) were prepared using the thin-film hydration method and characterized by Fourier-transform infrared spectroscopy (FTIR), field-emission scanning electron microscopy (FESEM), and dynamic light scattering (DLS). SKOV3 ovarian cancer cells were treated with free kaempferol (free KMF) or KMF Niosomes (0.00625-0.8 mg/mL) for 24, 48, and 72 h. Cell viability was evaluated using the MTT assay, whereas apoptosis and cell-cycle distribution were assessed by flow cytometry. The relative expression levels of BAX, TP53, BCL2, and MMP2 were determined by quantitative real-time PCR. RESULTS: Compared with free KMF, the niosomal formulation exhibited significantly greater cytotoxic activity, resulting in lower IC₅₀ values at all evaluated time points. It also produced greater modulation of apoptosis-related gene expression, characterized by increased expression of BAX and TP53 together with reduced expression of BCL2. In addition, treatment with the niosomal formulation was associated with reduced expression of the migration-associated gene MMP2 at the mRNA level. Flow cytometric analysis further demonstrated an increased proportion of cells in the G/G phase and a higher proportion of apoptotic cells in cells treated with KMF Niosomes than in those treated with free KMF. CONCLUSIONS: Collectively, these findings suggest that niosomal encapsulation enhances the in vitro anticancer activity of kaempferol against SKOV3 ovarian cancer cells and is associated with transcriptional modulation of apoptosis-related genes, cell-cycle progression, and migration-associated cellular responses. However, because drug-release kinetics, formulation stability, intracellular uptake, protein-level validation, and in vivo therapeutic efficacy were not evaluated, the mechanisms underlying the enhanced biological activity cannot be conclusively established. Therefore, further mechanistic and in vivo studies are warranted to validate these findings and to determine the translational potential of this niosomal delivery system for ovarian cancer therapy. |
Molecular biology reports | 2026 Oct 25 | PubMed |
| 15 |
Expression of TCTP/HRF and MCL-1 in chronic lymphocytic leukemia: implications for disease pathogenesis.
View abstractBACKGROUND: Chronic lymphocytic leukemia (CLL) is characterized by defective apoptosis and overexpression of anti-apoptotic proteins. Translationally Controlled Tumor Protein/Histamine-Releasing Factor (TCTP/HRF) is a highly conserved multifunctional protein with anti-apoptotic properties that stabilizes myeloid leukemia cell differentiation protein (Mcl-1). OBJECTIVE: To investigate TCTP and Mcl-1 expression levels in CLL patients compared with healthy controls and examine their clinical correlations. METHODS: We analyzed mRNA and protein levels of TCTP using Quantitative PCR (qPCR) and flow cytometry in 54 CLL patients and 22 healthy controls. Clinical parameters, prognostic markers, and cytogenetic abnormalities were correlated with expression levels. RESULTS: Both TCTP and Mcl-1 mRNA and protein levels were significantly elevated in CLL patients compared with controls. TCTP and Mcl-1 protein expression levels showed a strong positive correlation. TCTP mRNA, Mcl-1 mRNA, TCTP protein, and Mcl-1 protein expression levels were positively correlated with lymphocyte counts in the evaluable CLL cohort, whereas TCTP mRNA, TCTP protein, and Mcl-1 protein expression levels were inversely correlated with platelet counts in newly diagnosed patients. TCTP and Mcl-1 mRNA expression levels were significantly lower in ZAP-70-positive patients. No significant associations were observed with disease stage, cytogenetic abnormalities, or CD38 expression. CONCLUSIONS: These findings suggest a potential role for the TCTP/Mcl-1 axis in CLL pathogenesis and progression, warranting further investigation as therapeutic targets. |
Molecular biology reports | 2026 Oct 25 | PubMed |
| 16 |
Reshaping the tumor immune microenvironment via therapy-induced senescence: senescence-associated secretory phenotype networks and senolytic strategies.
View abstractAnticancer therapy can suppress tumor growth by inducing cell death, but many treatments also impose durable stress programs in malignant and stromal cells. Therapy-induced senescence (TIS) has emerged as a central non-lethal outcome of chemotherapy, radiotherapy and targeted therapy. Senescent cells remain metabolically active and communicate with their surroundings through the senescence-associated secretory phenotype (SASP), a heterogeneous mixture of cytokines, chemokines, growth factors, proteases, extracellular vesicles and immune-modulatory signals. In cancer, this secretory program can support immune surveillance when it is transient and efficiently cleared, yet it can also promote chronic inflammation, immune suppression, stromal remodeling, recurrence and resistance when senescent cells persist. This review summarizes the TIS-SASP-tumor immune microenvironment (TIME) axis, with emphasis on the molecular regulation of SASP, immune-cell-specific remodeling, the biphasic nature of SASP-mediated immunity and the rationale for sequential senogenic-senolytic therapy. Here, "senogenic" refers to interventions that induce cellular senescence, "senolytic" to approaches that selectively eliminate senescent cells, and "senomorphic" to strategies that suppress or remodel harmful senescence-associated phenotypes without necessarily killing senescent cells. We discuss how senolytics, senomorphics and immune checkpoint combinations may convert therapy-induced senescence from a liability into a therapeutically exploitable state. We also highlight the translational barriers that currently limit this strategy, including biomarker specificity, cell-type heterogeneity, treatment timing, safety and the need for spatially resolved monitoring of senescent niches. |
Molecular biology reports | 2026 Oct 25 | PubMed |
| 17 |
Intratarsal keratinous cyst: clinical characteristics and surgical outcomes of T-shaped eyelid pentagonal wedge resection.
View abstractPURPOSE: To describe the clinical characteristics of intratarsal keratinous cyst (IKC) and to evaluate the surgical outcomes of T-shaped eyelid pentagonal wedge resection. METHODS: A retrospective observational study of patients with IKCs who underwent surgery by a single surgeon. Data on patient demographics, clinical findings, and surgical outcomes were obtained. Surgery included an eyelid crease incision in the upper eyelid and a subciliary incision in the lower eyelid, complete cystectomy, full-thickness eyelid margin pentagonal wedge resection, wound closure, and temporary placement of soft contact lens to prevent postoperative ocular surface damage. RESULTS: This study included 14 patients (8 males and 6 females; mean age, 69.0 years). IKCs most frequently involved the upper eyelid (11 patients, 78.6%). Five patients (35.7%) were misdiagnosed and treated as chalazion. A whitish or grayish non-inflamed lesion was transparently observed through the palpebral conjunctiva in 12 patients (85.7%). Over a mean follow-up of 10.2 months, no recurrences were observed. All patients obtained cosmetically acceptable outcomes without corneal abrasion during blinking. CONCLUSION: IKCs predominantly occur in the upper eyelid, and approximately one-third of patients were initially misdiagnosed as chalazion. T-shaped eyelid pentagonal wedge resection is a safe and effective treatment for IKCs without recurrence, providing complete lesion removal and achieving favorable cosmetic outcomes while minimizing the risk of postoperative ocular surface irritation. |
International ophthalmology | 2026 Oct 25 | PubMed |
| 18 |
Long-term outcomes of retinal vasoproliferative tumors and response-based classification.
View abstractPURPOSE: To present the clinical features, management modalities, and response to treatment of the retinal vasoproliferative tumors (VPT) in a tertiary eye center. METHODS: This is a retrospective interventional cohort study that included patients diagnosed with VPT between 2014 and 2024. The medical records of all patients were retrospectively reviewed. RESULTS: Eighteen eyes of 15 patients (44.12%) were included. The mean age of patients was 42.0 ± 12.6 years. The mean duration of follow-up was 70.6 ± 37.0 months. The most common location of VPT was inferotemporal (83.3%). Associated findings included subretinal fluid (100%), subretinal or intraretinal exudation (100%), and cystoid macular edema (66.7%). Significant visual improvements were achieved after intravitreal injections of bevacizumab, aflibercept, triamcinolone, and dexamethasone (P = 0.026), while significant reductions of the central subfoveal thickness were achieved after laser (P = 0.037) and pars plana vitrectomy (P = 0.034). Seven eyes had complete resolution, while 7 eyes had incomplete resolution, and 4 eyes had resistant tumors with clinical progression. The complete resolution type had significantly better visual outcomes than other types (P < 0.001). CONCLUSION: Subretinal fluid and intraretinal/subretinal exudations are prominent clinical features of VPT. There was a significant relationship between VPT classification based on the clinical response to treatment and the visual outcomes. |
International ophthalmology | 2026 Oct 25 | PubMed |
| 19 |
Leveraging claims data-based small-area estimation to evaluate endoscopy access and the area-level prevalence of being up-to-date with colorectal cancer screening among screen-eligible adults in North Carolina.
View abstractEndoscopy remains the most common modality by which screen-eligible adults are up-to-date with colorectal (CRC) screening. For the Area-Level Estimates of Cancer Screening (ALECS) study, we leveraged multi-payor claims data to generate small-area estimates of the prevalence of being up-to-date with colorectal cancer (CRC) screening among continuously insured screen-eligible adults in North Carolina (NC). First, we created bespoke small areas at the intersection of counties and ZIP codes, which enabled linkages with aggregated claims data using patients' residential ZIP codes and counties. Using a 10-year lookback period, we then defined the cohort as near-continuously insured screen-eligible adults age 50-74, who did not have a prior diagnosis of CRC or a total colectomy as of December 2020. Statewide, from 2012 to 2020, 79.8-81.2% of continuously insured screen-eligible adults aged 50-75 were up-to-date (UTD) on CRC screening. In 2020, at the small area level, the mean prevalence of being UTD with CRC screening was 79.6% (Standard Deviation: 9.5). Diagnostic tests of an Ordinary Least Squares (OLS) model indicated a significant degree of spatial dependence of the error terms (I = 0.1540; p<.00001), suggesting the need for spatial models. We thus fit a Conditional Autoregressive (CAR) Bayesian generalized linear model with a logistic link function and Leroux priors, accounting for spatial autocorrelation, and found an inverse association between the minimum distance to access an endoscopy facility and the prevalence of being up to date with CRC screening among continuously insured screen-eligible adults across NC (Point Estimate: - 0.0645; Credible Interval: - 0.1156 - 0.0103). |
Cancer causes & control : CCC | 2026 Oct 25 | PubMed |
| 20 |
Regorafenib induces ferroptosis in hepatocellular carcinoma via the EGFR-TNF/NF-κB signaling axis.
View abstractRegorafenib is a standard second-line multi-targeted tyrosine kinase inhibitor for sorafenib-resistant hepatocellular carcinoma (HCC). Ferroptosis is a promising therapeutic cell-death modality, but the upstream signaling events governing regorafenib-induced ferroptosis remain unclear. We examined regorafenib activity in treatment-naive SNU-449 and HuH-7 HCC cells and mouse tumor models using ferroptosis-related assays, including reactive oxygen species (ROS), malondialdehyde (MDA), labile Fe, lipid peroxidation and mitochondrial ultrastructure. Transcriptome profiling was integrated with genetic and pharmacological modulation of EGFR and p65. Antitumor effects were assessed in HuH-7 xenografts and Hepa1-6 syngeneic tumors. Regorafenib suppressed proliferation, migration, invasion, and tumor growth, with reduced Ki-67 expression. It downregulated SLC7A11/xCT and glutathione peroxidase 4 (GPX4) and increased ROS, labile Fe, lipid peroxidation, and MDA; ferrostatin-1 partially restored viability and attenuated lipid peroxidation. Transcriptome analysis identified enrichment of the TNF signaling pathway. Regorafenib reduced total and phosphorylated EGFR and p65, decreased the p-EGFR/EGFR and p-p65/p65 ratios, and inhibited p65 nuclear translocation. p65 knockdown decreased SLC7A11/xCT and GPX4 and intensified ferroptosis, whereas p65 overexpression attenuated these effects. EGFR knockdown reduced TNF-α and enhanced ferroptosis; the EGFR agonist NSC228155 restored NF-κB activity and SLC7A11/xCT-GPX4 expression. Combined EGFR knockdown and lenalidomide treatment further enhanced ferroptosis-associated phenotypes in vitro. Exploratory analysis of 24 paired specimens showed EGFR, p65, and GPX4 were upregulated and positively associated. These findings identify EGFR-TNF/NF-κB signaling as a functional upstream module in treatment-naive HCC models and support validating combined EGFR knockdown and lenalidomide treatment in resistant models. |
Apoptosis : an international journal on programmed cell death | 2026 Oct 25 | PubMed |
| 21 |
Nationwide practice patterns and local recurrence after surgery for benign bone tumours: a retrospective study using the Bone and Soft Tissue Tumor Registry in Japan.
View abstractPURPOSE: The epidemiology and treatment pathways of benign bone tumours remain poorly understood. Using the Bone and Soft Tissue Tumor Registry of the Japanese Orthopaedic Association, we aimed to clarify nationwide diagnostic and surgical practices and factors associated with postoperative local recurrence. METHODS: We retrospectively analysed registry data from 2006 to 2019. Logistic regression models were used for biopsy and surgery, and Cox proportional hazards models for local recurrence. RESULTS: We identified 28,075 cases across 19 histological subtypes. Biopsy was performed in 14.9% and surgery in 39.9%. Diagnostic and surgical management varied according to age, anatomical site, and subtype. Local recurrence occurred in 2.4% of surgical cases and was more common in children, cases referred after prior treatment, and specific subtypes, with the strongest association observed for aneurysmal bone cyst. CONCLUSION: These nationwide data provide a benchmark for current clinical practice in benign bone tumours. |
International orthopaedics | 2026 Oct 25 | PubMed |
| 22 |
A large-scale consensus study of a diagnostic algorithm for canine and feline mammary tumor histopathology: An attempt to improve inter-observer agreement.
View abstractHistological classification of mammary proliferative lesions in dogs and cats is essential for prognostic and predictive studies, as well as for comparative oncology; however, standardization of diagnoses is highly affected by substantial interobserver variability. In this study, a structured diagnostic algorithm based on the Davis-Thompson Foundation classification was assessed for the ability to improve interobserver agreement in the morphological diagnoses of mammary gland lesions in dogs and cats. Consensus diagnoses of 114 selected mammary lesions (91 canine, 23 feline) made by 16 veterinary pathologists with mammary tumor expertise were used as the gold standard, and 79 veterinary pathologists from 21 countries evaluated digitized whole slides in 2 rounds: a first reading without the algorithm and a second reading with the algorithm. Interobserver concordance was measured using unweighted kappa statistics for lesion category (hyperplastic/dysplastic, benign, malignant) and histological subtype. Across all lesions, agreement was higher for lesion category than for histological subtype. A slight improvement in concordance was observed when applying the algorithm, both for category (k = 0.72, before, and k = 0.73, after) and histotype classifications (k = 0.40, before to k = 0.42, after). Also, by using the algorithm, 73/79 raters (92%) modified at least 1 diagnosis and, among these, approximately two-thirds reached agreement with the gold standard in at least 1 case. Considering histotypes, malignant tumors with mixed epithelial and myoepithelial components showed persistently low agreement. Overall, the algorithm provided a reproducible diagnostic framework that may support training and improve standardization of canine and feline mammary tumor classification. |
Veterinary pathology | 2026 Oct 25 | PubMed |
| 23 |
Accidental overdose admissions and premature death: A large population-based data-linkage cohort study in New South Wales, Australia (PAVLOVA 4).
View abstractBACKGROUND AND AIMS: People with substance use disorders have reduced life-expectancy; however, risks of premature death from injuries and natural causes following an accidental overdose are not well characterised. This study aimed to estimate risk of premature death (by cause and over time), and disease burden following hospitalised accidental overdose. DESIGN: An observational study using the Poisoning And enVenomation Linkage to evaluate Outcomes and clinical Variation in Australia (PAVLOVA) cohort. SETTING: A population-based data-linkage including admissions from all public and private hospitals in New South Wales, Australia (population ~8 million), 2011-2020. PARTICIPANTS: 14 036 individuals [median age 43.5 years, interquartile range (IQR) = 29.4-61.8 years, 46.7% female, n = 6557] with an index non-fatal accidental poisoning, as defined by hospital coding, followed for a median of 3.9 years (IQR = 1.7-6.3). We restricted our analysis to people with accidental poisonings with prescription and illicit drugs that are associated with non-medical use and dependence, including opioids and benzodiazepines. MEASUREMENTS: Standardised mortality ratio (SMR) by cause (natural causes stratified by body system, and external causes stratified by intent and mechanism), SMR over time (post-index poisoning), years of life lost (YLL) by cause, age and sex. SMR and YLL were calculated based on expected values generated using official statistics. RESULTS: Of the 14 036 people included, there were 2588 deaths. Death was more likely in individuals with accidental poisoning compared with the general population [SMR = 3.5, 95% confidence interval (CI) = 3.4-3.7]. SMRs were highest for external causes (SMR = 12.8, 95% CI = 11.5-14.1), including accidental poisoning (SMR = 59.5, 95% CI = 51.7-67.3) and suicide (SMR = 10.5, 95% CI = 8.2-12.9). Death was also more likely across all natural causes, particularly infectious (SMR = 7.0, 95% CI = 5.1-8.9) and respiratory diseases (SMR = 6.2, 95% CI = 5.4-6.9). Median YLL per death was 21.2 (IQR = 10.0-35.6) and 15.2 (IQR = 7.2-30.2) for males and females, respectively. The main contributors to YLL were natural causes (64.0%): neoplasms (19.5%), circulatory (12.2%) and respiratory disease (11.1%). The remainder of YLL was from external causes (36.0%): mainly accidental poisoning (22.4%). SUMMARY: People in New South Wales, Australia, who experience an accidental overdose appear to have an increased risk of death over subsequent years, but particularly in the first month, compared with the general population; however, accidental poisoning accounts for only 22% of years of life lost, with death from natural causes being much more common. |
Addiction (Abingdon, England) | 2026 Oct 25 | PubMed |
| 24 |
A pediatric high-grade B-cell lymphoma with a rare complex cytogenetic profile: A case report.
View abstractINTRODUCTION: Pediatric B non-Hodgkin lymphoma (B-NHL) often presents with complex karyotypes (CK), co-occurring high-risk mutations, and treatment resistance, leading to poor outcomes. CASE DESCRIPTION: We describe a child with a CK including translocation, inversion, deletion, gain, and loss, exhibiting a high tumor burden and a partial response to standard therapy, requiring treatment intensification. CONCLUSION: This case emphasizes the critical role of comprehensive cytogenetic and molecular profiling to guide diagnosis, risk stratification, and therapy selection. Recognition of high-risk genetic features can inform early intensification or targeted approaches. Pediatric -rearranged B-NHL with complex cytogenetics remains under-characterized but clinically aggressive, underscoring the need for multicenter studies to define its genetic spectrum, refine prognostic models, and optimize individualized treatment strategies. |
Tumori | 2026 Oct 25 | PubMed |
| 25 |
Deubiquitinase USP5 suppresses ferroptosis in lung adenocarcinoma by deubiquitinating and stabilizing GPX3.
View abstractFerroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation and has emerged as a promising therapeutic target in nonsmall cell lung cancer (NSCLC). However, the specific mechanisms by which nonsmall cell lung cancer cells evade ferroptosis remain to be further elucidated. We conducted integrative transcriptomic analyses of published NSCLC datasets to identify ubiquitin-specific proteases (USPs) potentially involved in the regulation of ferroptosis. Multiple USP proteins were screened and their prognostic significance evaluated, ultimately selecting USP5 for functional studies in two lung adenocarcinoma (LUAD) cell lines and patient-derived LUAD organoids. Following treatment with the ferroptosis inducer erastin, survival rates and metastatic capacity were assessed. Ferroptosis was evaluated by measuring established ferroptotic markers and examining mitochondrial ultrastructure. Protein interactions were investigated using mass spectrometry, immunoprecipitation, and GST pull-down assays. USP5 was significantly upregulated in LUAD tissues and correlated with poor patient prognosis. Functional experiments demonstrated that USP5 suppresses ferroptosis in LUAD cells treated with erastin, thereby promoting cell survival, proliferation, and invasiveness. Mechanistically, USP5 directly binds to and deubiquitinates GPX3, a key antioxidant enzyme, to enhance its stability. Rescue experiments confirmed that GPX3 is a functional mediator of USP5's ferroptosis-inhibitory role. These findings are further supported in patient-derived LUAD organoids. Our study identifies USP5 as a critical suppressor of ferroptosis in LUAD through its stabilization of GPX3, revealing a novel USP5-GPX3 regulatory axis that enables tumor resistance to oxidative stress. Targeting this pathway may represent a promising therapeutic strategy. |
Journal of cell communication and signaling | 2026 Dec | PubMed |
| 26 | Genomic landscape of cholangiocarcinoma in India: ethnic variants and implications for targeted therapy | BMC Cancer | 2026 | Scholar |
| 27 | Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS). | JCO global oncology | 2026 | Scholar |
| 28 | Resection margin width as a risk factor for liver cancer recurrence | Russian Journal of Oncology | 2026 | Scholar |
| 29 | Abstract 1137: Validation of a sensitive, tissue-free blood test for biomarker discovery and tumor burden assessment | Cancer Research | 2026 | Scholar |
| 30 | First-line pembrolizumab plus chemotherapy versus bevacizumab plus chemotherapy in response and survival outcomes in PD-L1-negative advanced non-squamous NSCLC: a retrospective comparative cohort study | Translational Lung Cancer Research | 2026 | Scholar |
| 31 | Listening to children's voices: Psychosocial and behavioral experiences and identity-related changes during the cancer trajectory | Asia-Pacific Journal of Oncology Nursing | 2026 | Scholar |
| 32 | Unveiling trends and clinical progress of immunotherapy for endometrial cancer: a scientometric and clinical trial landscape analysis | Frontiers in Immunology | 2026 | Scholar |
| 33 | Non-Diabetic Insulin Use in the Treatment of Neoplasms: A Pilot Study on the Insulin Potentiation Technique and p53 Expression | Endocrine System and Diabetes | 2026 | Scholar |

